Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.56 EUR
−189.58 M EUR
105.40 M EUR
195.06 M
About Esperion Therapeutics, Inc.
Sector
CEO
Sheldon L. Koenig
Headquarters
Ann Arbor
Website
Founded
1998
FIGI
BBG007HLD3L5
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
PFE5307022
Esperion Therapeutics, Inc. 4.0% 15-NOV-2025Yield to maturity
8.12%
Maturity date
Nov 15, 2025
Explore more bonds
Frequently Asked Questions
The current price of 0ET is 2.37 EUR — it has increased by 2.65% in the past 24 hours. Watch ESPERION THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ESPERION THERAPEUTICS INC stocks are traded under the ticker 0ET.
0ET stock has risen by 11.65% compared to the previous week, the month change is a 28.89% rise, over the last year ESPERION THERAPEUTICS INC has showed a 118.76% increase.
We've gathered analysts' opinions on ESPERION THERAPEUTICS INC future price: according to them, 0ET price has a max estimate of 14.81 EUR and a min estimate of 1.90 EUR. Watch 0ET chart and read a more detailed ESPERION THERAPEUTICS INC stock forecast: see what analysts think of ESPERION THERAPEUTICS INC and suggest that you do with its stocks.
0ET stock is 8.07% volatile and has beta coefficient of 3.01. Track ESPERION THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is ESPERION THERAPEUTICS INC there?
Today ESPERION THERAPEUTICS INC has the market capitalization of 450.40 M, it has increased by 14.62% over the last week.
Yes, you can track ESPERION THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
ESPERION THERAPEUTICS INC is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
0ET earnings for the last quarter are −0.13 EUR per share, whereas the estimation was −0.16 EUR resulting in a 14.42% surprise. The estimated earnings for the next quarter are −0.13 EUR per share. See more details about ESPERION THERAPEUTICS INC earnings.
ESPERION THERAPEUTICS INC revenue for the last quarter amounts to 46.37 M EUR, despite the estimated figure of 46.08 M EUR. In the next quarter, revenue is expected to reach 57.80 M EUR.
0ET net income for the last quarter is −26.52 M EUR, while the quarter before that showed −57.81 M EUR of net income which accounts for 54.13% change. Track more ESPERION THERAPEUTICS INC financial stats to get the full picture.
No, 0ET doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 240.00 employees. See our rating of the largest employees — is ESPERION THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ESPERION THERAPEUTICS INC EBITDA is 26.58 M EUR, and current EBITDA margin is −133.58%. See more stats in ESPERION THERAPEUTICS INC financial statements.
Like other stocks, 0ET shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ESPERION THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ESPERION THERAPEUTICS INC technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ESPERION THERAPEUTICS INC stock shows the neutral signal. See more of ESPERION THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.